These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 19540875)

  • 1. Antipsychotic drug actions on gene modulation and signaling mechanisms.
    Molteni R; Calabrese F; Racagni G; Fumagalli F; Riva MA
    Pharmacol Ther; 2009 Oct; 124(1):74-85. PubMed ID: 19540875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Messing up with traffic: different effects of antipsychotic agents on glutamate receptor complexes in vivo.
    Del'guidice T; Beaulieu JM
    Mol Pharmacol; 2008 May; 73(5):1339-42. PubMed ID: 18314495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New pharmacological approaches to the treatment of schizophrenia].
    Uzbay IT
    Turk Psikiyatri Derg; 2009; 20(2):175-82. PubMed ID: 19504368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.
    Miyamoto S; Duncan GE; Marx CE; Lieberman JA
    Mol Psychiatry; 2005 Jan; 10(1):79-104. PubMed ID: 15289815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mechanisms of psychostimulant addiction.
    Chen JC; Chen PC; Chiang YC
    Chang Gung Med J; 2009; 32(2):148-54. PubMed ID: 19403004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychosis pathways converge via D2high dopamine receptors.
    Seeman P; Schwarz J; Chen JF; Szechtman H; Perreault M; McKnight GS; Roder JC; Quirion R; Boksa P; Srivastava LK; Yanai K; Weinshenker D; Sumiyoshi T
    Synapse; 2006 Sep; 60(4):319-46. PubMed ID: 16786561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents.
    Miyamoto S; Miyake N; Jarskog LF; Fleischhacker WW; Lieberman JA
    Mol Psychiatry; 2012 Dec; 17(12):1206-27. PubMed ID: 22584864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Psychotropic drugs and the involvement of the Akt/GSK3 signalling pathway in mental illnesses].
    Del'Guidice T; Beaulieu JM
    Med Sci (Paris); 2010; 26(6-7):647-51. PubMed ID: 20619169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do neurotensin receptor agonists represent a novel class of antipsychotic drugs?
    Cáceda R; Kinkead B; Nemeroff CB
    Semin Clin Neuropsychiatry; 2003 Apr; 8(2):94-108. PubMed ID: 12728409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The dopamine D4 receptors and mechanisms of antipsychotic atypicality.
    Wong AH; Van Tol HH
    Prog Neuropsychopharmacol Biol Psychiatry; 2003 Oct; 27(7):1091-9. PubMed ID: 14642969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The mechanisms of action of antipsychotic drugs: is atypicality superior in schizophrenia treatment?].
    Anil Yağcioğlu AE
    Turk Psikiyatri Derg; 2007; 18(4):364-74. PubMed ID: 18066727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PKC, MAP kinases and the bcl-2 family of proteins as long-term targets for mood stabilizers.
    Manji HK; Chen G
    Mol Psychiatry; 2002; 7 Suppl 1():S46-56. PubMed ID: 11986995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylation of FADD (Fas-associated death domain protein) at serine 194 is increased in the prefrontal cortex of opiate abusers: relation to mitogen activated protein kinase, phosphoprotein enriched in astrocytes of 15 kDa, and Akt signaling pathways involved in neuroplasticity.
    Ramos-Miguel A; García-Fuster MJ; Callado LF; La Harpe R; Meana JJ; García-Sevilla JA
    Neuroscience; 2009 Jun; 161(1):23-38. PubMed ID: 19303913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers.
    Chen G; Manji HK
    Curr Opin Psychiatry; 2006 May; 19(3):313-23. PubMed ID: 16612219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brain-derived neurotropic factor/TrkB signaling in the pathogenesis and novel pharmacotherapy of schizophrenia.
    Pillai A
    Neurosignals; 2008; 16(2-3):183-93. PubMed ID: 18253057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antipsychotic-associated neuronal changes in the brain: toxic, therapeutic, or irrelevant to the long-term outcome of schizophrenia?
    Dean CE
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):174-89. PubMed ID: 16376473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PKA-mediated responses in females' estrous cycle affect cocaine-induced responses in dopamine-mediated intracellular cascades.
    Weiner J; Sun WL; Zhou L; Kreiter CM; Jenab S; Quiñones-Jenab V
    Neuroscience; 2009 Jul; 161(3):865-76. PubMed ID: 19348873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impairments of neuroplasticity and cellular resilience in severe mood disorders: implications for the development of novel therapeutics.
    Manji HK; Duman RS
    Psychopharmacol Bull; 2001; 35(2):5-49. PubMed ID: 12397885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The complexity of the dopaminergic synapses and their modulation by antipsychotics.
    Leuner K; Müller WE
    Pharmacopsychiatry; 2006 Feb; 39 Suppl 1():S15-20. PubMed ID: 16508891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overview of the mechanism of action of lithium in the brain: fifty-year update.
    Lenox RH; Hahn CG
    J Clin Psychiatry; 2000; 61 Suppl 9():5-15. PubMed ID: 10826655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.